Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2002-01-25
- Employees
- 1K
- Market Cap
- -
- Website
- https://www.3s-guojian.com
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-01-12
- Target Recruit Count
- 90
- Registration Number
- NCT05865496
- Locations
- 🇨🇳
Site 02, Xuzhou, Jiangsu, China
🇨🇳Site 01, Beijing, Beijing, China
🇨🇳Site 03, Beijing, Beijing, China
Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2022-12-07
- Target Recruit Count
- 24
- Registration Number
- NCT05641558
- Locations
- 🇨🇳
Nanyang First People's Hospital, Nanyang, Henan, China
🇨🇳Peking University Shougang Hospital, Beijing, Beijing, China
🇨🇳Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, China
A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2022-11-08
- Target Recruit Count
- 139
- Registration Number
- NCT05604898
- Locations
- 🇨🇳
Shanghai Dermatology Hospital, Shanghai, Shanghai, China
🇨🇳Huashan Hospital Fudan University, Shanghai, Shanghai, China
🇨🇳The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
- Conditions
- Interventions
- Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib)Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II)Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II)Drug: Compound Betamethasone Injection (phase II)Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib)Other: Placebo (phase II)
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2022-10-20
- Target Recruit Count
- 120
- Registration Number
- NCT05588908
- Locations
- 🇨🇳
Site 02, Wuhan, Hubei, China
🇨🇳Site 01, Shanghai, Shanghai, China
🇨🇳Site 03, Linyi, Shandong, China
A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma
- Conditions
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2022-10-18
- Target Recruit Count
- 24
- Registration Number
- NCT05584306
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2024-02-01
- Target Recruit Count
- 93
- Registration Number
- NCT05544591
- Locations
- 🇨🇳
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China
A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2023-01-13
- Target Recruit Count
- 450
- Registration Number
- NCT05536726
- Locations
- 🇨🇳
Shanghai Huanshan Hospital Fudan University, Shanghai, Shanghai, China
A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2022-09-06
- Target Recruit Count
- 120
- Registration Number
- NCT05528679
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-01-13
- Target Recruit Count
- 350
- Registration Number
- NCT05520177
- Locations
- 🇨🇳
TianJin Eye Hospital, Tianjin, Tianjin, China
🇨🇳The Second XiangYa Hospital of Central South University, Changsha, Hunan, China
🇨🇳ZheJiang Province People's Hospital, HangZhou, Zhejiang, China
A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2022-01-14
- Target Recruit Count
- 30
- Registration Number
- NCT05193214
- Locations
- 🇨🇳
Beijing Jishuitan Hospital, Beijing, Beijing, China